Last edition
Gland Pharma Limited - Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad
The United States Food and Drug Administration (US FDA) has conducted Good Manufacturing Practice (GMP) Inspection at Gland Pharma Limited's Dundigal Facility at Hyderabad between 03rd July, 2023 and 14th July, 2023.
The inspection was concluded with ONE (1) 483 Observation. The corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy